ERAMET (ERA.PA) Fundamental Analysis & Valuation

EPA:ERA • FR0000131757

Current stock price

53.95 EUR
-1.95 (-3.49%)
Last:

This ERA.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ERA.PA Profitability Analysis

1.1 Basic Checks

  • ERA had negative earnings in the past year.
  • ERA had a negative operating cash flow in the past year.
  • Of the past 5 years ERA 4 years were profitable.
  • In multiple years ERA reported negative operating cash flow during the last 5 years.
ERA.PA Yearly Net Income VS EBIT VS OCF VS FCFERA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

1.2 Ratios

  • ERA's Return On Assets of -8.11% is on the low side compared to the rest of the industry. ERA is outperformed by 79.55% of its industry peers.
  • ERA has a Return On Equity of -66.43%. This is amonst the worse of the industry: ERA underperforms 90.91% of its industry peers.
Industry RankSector Rank
ROA -8.11%
ROE -66.43%
ROIC N/A
ROA(3y)-2.05%
ROA(5y)1.79%
ROE(3y)-19.55%
ROE(5y)2.47%
ROIC(3y)N/A
ROIC(5y)N/A
ERA.PA Yearly ROA, ROE, ROICERA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60 -80

1.3 Margins

  • The Gross Margin of ERA (63.17%) is better than 88.64% of its industry peers.
  • In the last couple of years the Gross Margin of ERA has declined.
  • ERA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5Y-1.74%
ERA.PA Yearly Profit, Operating, Gross MarginsERA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ERA.PA Health Analysis

2.1 Basic Checks

  • ERA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ERA has less shares outstanding
  • The number of shares outstanding for ERA has been increased compared to 5 years ago.
  • Compared to 1 year ago, ERA has a worse debt to assets ratio.
ERA.PA Yearly Shares OutstandingERA.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
ERA.PA Yearly Total Debt VS Total AssetsERA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • ERA has an Altman-Z score of 0.88. This is a bad value and indicates that ERA is not financially healthy and even has some risk of bankruptcy.
  • ERA has a Altman-Z score of 0.88. This is amonst the worse of the industry: ERA underperforms 84.09% of its industry peers.
  • ERA has a Debt/Equity ratio of 3.06. This is a high value indicating a heavy dependency on external financing.
  • With a Debt to Equity ratio value of 3.06, ERA is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.06
Debt/FCF N/A
Altman-Z 0.88
ROIC/WACCN/A
WACC9.47%
ERA.PA Yearly LT Debt VS Equity VS FCFERA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B

2.3 Liquidity

  • A Current Ratio of 1.37 indicates that ERA should not have too much problems paying its short term obligations.
  • ERA has a Current ratio of 1.37. This is in the lower half of the industry: ERA underperforms 75.00% of its industry peers.
  • A Quick Ratio of 0.92 indicates that ERA may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.92, ERA is not doing good in the industry: 65.91% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 0.92
ERA.PA Yearly Current Assets VS Current LiabilitesERA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ERA.PA Growth Analysis

3.1 Past

  • ERA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -3948.08%.
  • The Revenue has decreased by -6.14% in the past year.
  • The Revenue has been decreasing by -0.28% on average over the past years.
EPS 1Y (TTM)-3948.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-706.79%
Revenue 1Y (TTM)-6.14%
Revenue growth 3Y-18.11%
Revenue growth 5Y-0.28%
Sales Q2Q%-8.91%

3.2 Future

  • The Earnings Per Share is expected to grow by 32.30% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ERA will show a small growth in Revenue. The Revenue will grow by 1.03% on average per year.
EPS Next Y36.49%
EPS Next 2Y30.76%
EPS Next 3Y32.3%
EPS Next 5YN/A
Revenue Next Year2.81%
Revenue Next 2Y5.29%
Revenue Next 3Y1.03%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ERA.PA Yearly Revenue VS EstimatesERA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B 5B
ERA.PA Yearly EPS VS EstimatesERA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

1

4. ERA.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ERA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ERA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ERA.PA Price Earnings VS Forward Price EarningsERA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • 61.36% of the companies in the same industry are more expensive than ERA, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.86
ERA.PA Per share dataERA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80

4.3 Compensation for Growth

  • ERA's earnings are expected to grow with 32.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.76%
EPS Next 3Y32.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ERA.PA Dividend Analysis

5.1 Amount

  • No dividends for ERA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ERA.PA Fundamentals: All Metrics, Ratios and Statistics

ERAMET

EPA:ERA (4/24/2026, 7:00:00 PM)

53.95

-1.95 (-3.49%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)04-23
Earnings (Next)07-28
Inst Owners16.96%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.55B
Revenue(TTM)2.75B
Net Income(TTM)-477.00M
Analysts78
Price Target54.47 (0.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend1.51
Dividend Growth(5Y)-8.12%
DP-9.01%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.48%
PT rev (3m)-1.29%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-784.38%
EPS NY rev (3m)-701.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.58%
Revenue NY rev (3m)-4.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.56
P/FCF N/A
P/OCF N/A
P/B 2.16
P/tB 4.2
EV/EBITDA 9.86
EPS(TTM)-16.68
EYN/A
EPS(NY)-6.23
Fwd EYN/A
FCF(TTM)-27.29
FCFYN/A
OCF(TTM)-10.88
OCFYN/A
SpS95.72
BVpS24.97
TBVpS12.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -8.11%
ROE -66.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.17%
FCFM N/A
ROA(3y)-2.05%
ROA(5y)1.79%
ROE(3y)-19.55%
ROE(5y)2.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5Y-1.74%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 3.06
Debt/FCF N/A
Debt/EBITDA 6.58
Cap/Depr 101.29%
Cap/Sales 17.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 0.92
Altman-Z 0.88
F-Score2
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)258.05%
Cap/Depr(5y)220.45%
Cap/Sales(3y)20.76%
Cap/Sales(5y)16.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3948.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-706.79%
EPS Next Y36.49%
EPS Next 2Y30.76%
EPS Next 3Y32.3%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.14%
Revenue growth 3Y-18.11%
Revenue growth 5Y-0.28%
Sales Q2Q%-8.91%
Revenue Next Year2.81%
Revenue Next 2Y5.29%
Revenue Next 3Y1.03%
Revenue Next 5YN/A
EBIT growth 1Y-237.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5639.65%
EBIT Next 3Y317.49%
EBIT Next 5YN/A
FCF growth 1Y3.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-150.4%
OCF growth 3YN/A
OCF growth 5YN/A

ERAMET / ERA.PA Fundamental Analysis FAQ

What is the fundamental rating for ERA stock?

ChartMill assigns a fundamental rating of 2 / 10 to ERA.PA.


Can you provide the valuation status for ERAMET?

ChartMill assigns a valuation rating of 1 / 10 to ERAMET (ERA.PA). This can be considered as Overvalued.


How profitable is ERAMET (ERA.PA) stock?

ERAMET (ERA.PA) has a profitability rating of 2 / 10.


How financially healthy is ERAMET?

The financial health rating of ERAMET (ERA.PA) is 1 / 10.


Is the dividend of ERAMET sustainable?

The dividend rating of ERAMET (ERA.PA) is 0 / 10 and the dividend payout ratio is -9.01%.